Available as a daily pill or weekly injection

What is Compounding?

Compounding is the process of combining, mixing, or altering ingredients to create a medication tailored to the needs of an individual patient. While traditional compounding is vital for patients with specific allergies or needs, "compounded GLP-1s" have emerged as a way to circumvent shortages and high prices.

The Regulatory Landscape

The FDA has taken an increasingly aggressive stance against compounded GLP-1 medications. In 2024 and 2025, the agency issued warning letters to multiple compounding pharmacies for manufacturing violations, contamination concerns, and marketing unapproved versions of semaglutide and tirzepatide. The FDA has also explicitly stated that compounded versions of these drugs are not FDA-approved and has not verified their safety, effectiveness, or quality.

As brand-name supply stabilizes, the legal basis for compounding these medications is narrowing. Under federal law, compounding pharmacies can only produce copies of FDA-approved drugs when those drugs are on the FDA Drug Shortage List. Once a medication is removed from that list, compounding pharmacies are required to stop producing it. Tirzepatide (the active ingredient in Zepbound®) has already been removed from the shortage list, and semaglutide (Wegovy®) is expected to follow.

For patients currently on compounded GLP-1s, this creates a real risk: your medication supply could be discontinued with little notice, leaving you without treatment and forced to restart the process elsewhere. Choosing FDA-approved medications from the start eliminates that uncertainty entirely.

What Happens When Shortages End?

The GLP-1 shortage that fueled the compounding boom is ending. Novo Nordisk and Eli Lilly have dramatically expanded manufacturing capacity, and both now offer direct-to-patient pharmacy programs — NovoCare and LillyDirect — with fixed cash-pay pricing that didn't exist when the shortage began.

This changes the equation entirely. The two reasons patients turned to compounded GLP-1s — availability and affordability — are no longer barriers. Oral Wegovy® is available at $149/month, injectable Wegovy® at $199/month, and Zepbound® Vials and KwikPen at $299/month, all without insurance. These prices are comparable to, and in many cases lower than, what compounding telehealth providers charge for their unapproved alternatives.

As shortages resolve and the FDA restricts compounding, patients on compounded medications will need to transition to FDA-approved options regardless. Starting with the real thing now — or switching before you're forced to — means no disruption to your treatment, no gaps in medication, and no uncertainty about what you're putting in your body.

Price vs. Peace of Mind

Compounded semaglutide typically costs $200–400/month from other telehealth providers — without FDA approval, manufacturing oversight, or guaranteed potency. Through Imbue Health's manufacturer partnerships, FDA-approved Oral Wegovy® starts at $149/month, injectable Wegovy® starts at $199/month, and Zepbound® Vials and KwikPen start at $299/month. Brand-name quality at a comparable or lower price than most compounded alternatives.